Genmab A/S (GMAB): A Bull Case Theory
We came across a bullish thesis on Genmab A/S (GMAB) on Substack by Oliver | MMMT Wealth. In this article, we will summarize ...
Morgan Stanley Keeps Their Hold Rating on Genmab (GMAB)
In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Genmab (GMAB – Research Report), with a price target ...
Truist Financial Reaffirms Their Buy Rating on Genmab (GMAB)
Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Genmab (GMAB – Research Report) today. The company’s shares closed ...
Applied Clinical Trials Online1d
Genmab’s Rinatabart Sesutecan Continues Success in Advanced Ovarian Cancer Clinical Trials
New data from the Phase II RAINFOL-01 study shows rinatabart sesutecan (Rina-S), an investigative antibody-drug conjugate, ...
Investigational Rinatabart Sesutecan (Rina-S®) Continues To Show Encouraging Antitumor Activity In Patients With Advanced Ovarian Cancer
Results from Phase 2 RAINFOL TM -01 trial (B1 cohort) showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m 2 led to a confirmed objective response rate (ORR) of 55.6% and median ...
CWEB4d
Genmab A/S (NASDAQ:GMAB) Sees Positive Analyst Attention and Share Transactions Disclosure
GMAB, is a biotechnology company known for its innovative antibody therapeutics. Established in 1999 and based in Copenhagen, ...
Genmab: GEN3014's Demise And Implications For The HexaBody Platform
Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...
William Blair Increases Earnings Estimates for Genmab A/S
William Blair upped their FY2028 EPS estimates for Genmab A/S in a research note issued on Monday, March 10th. William Blair ...
Genmab A/S (NASDAQ:GMAB) Shares Sold by Assetmark Inc.
Assetmark Inc. lowered its position in Genmab A/S (NASDAQ:GMAB – Free Report) by 78.1% during the fourth quarter, Holdings ...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in ...
Passing of Genmab A/S' Annual General Meeting
Company Announcement At Genmab A/S' Annual General Meeting held today March 12, 2025, the Annual Report for 2024 was approvedDischarge was given to the Board of Directors and the Executive Management ...